Biotechnology

As RenovoRx preps its Q2 update, it's proving its mettle on two fronts: impressive sales of its RenovoCath device and a critical milestone in its pancreatic cancer trial.

The FNIH is launching a landmark study using AI and biomarkers to redefine depression, moving beyond guesswork toward precision care for millions.

As Akebia Therapeutics preps its Q2 report, all eyes are on Vafseo's uptake, a declining Auryxia, and a costly R&D push into rare kidney diseases.

With a novel drug targeting an unaddressed cause of glaucoma, Qlaris Bio adds a seasoned expert to its board, signaling a pivotal push toward market entry.

Processa Pharmaceuticals acquires Vidya Therapeutics and its key asset, VT-7208, backed by a $200M financing that radically overhauls the company's strategy.

A new study on umbilical cord allografts offers hope for chronic neck pain, but a closer look reveals the complex scientific and regulatory networks that will define its future.

For the sixth year, WuXi Biologics has secured a top ESG rating. This isn't just an award; it's a look inside a strategic overhaul of pharmaceutical manufacturing.

A Cleveland-based innovator rebrands, signaling a major shift from passive wound care to active biomaterials designed to guide regeneration and defeat infection.

By selling its mass cytometry unit and securing a $30M payout, Standard BioTools is fortifying its balance sheet for a transformative merger with Treeline.

Pluri's subsidiary Cellav just won UK approval for its aesthetic product. But the real story is the science and a market potentially 4x larger than stated.

Oak Hill Bio is betting on a therapy shelved by a pharma giant. Its new trial for Angelman syndrome tests a disruptive model for rare disease innovation.

A new biotech, CORE Biomedicine, armed with Eisai's preclinical assets and a $21M Series A, aims to upend oncology by targeting cancer's 'lineage' identity.

Dasher Neuroscience completes Phase 2 enrollment for its AI-designed drug for MSA, a fatal disease with no cure, signaling a major step toward a first-in-class therapy.

With $21M in funding and a novel 'lineage-based' approach, CORE Biomedicine is moving beyond genomics to target the root cause of cancer's identity.

Singapore's EUDA Health is moving from wellness products to pioneering 'off-the-shelf' cell therapies for cancer, a risky but potentially transformative leap.

ADMA Biologics reported 20% growth, but a lawsuit alleges it was a sham built on channel stuffing and hidden deals. Here's what investors need to know.

An Australian biotech's breakthrough study on fucoidan, a seaweed compound, offers a safe, clinically-proven new option for men suffering from BPH.

An upcoming summit for LGMD isn't just another conference. It's a key signal that patient advocacy, biotech innovation, and regulatory shifts are converging.

FDA clears a pivotal study for Medicus Pharma's SkinJect, a microneedle patch offering new hope for Gorlin Syndrome and a new playbook in biotech strategy.